ST-067 with CAR T-cell therapy for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have large B-cell lymphoma that has not responded to at least two prior treatments or has come back.
- Your cancer shows activity on a PET scan or biopsy, and your tumor cells have the CD19 protein.
- You are in fairly good health, able to care for yourself (Karnofsky score 60% or higher), and your major organs (heart, lungs, liver, kidneys) are working well enough.
- You have not had CAR T-cell therapy before, are not pregnant or breastfeeding, and do not have active infections like hepatitis B/C or HIV.
- You are not taking high-dose steroids or other strong immune-suppressing medicines within a week of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.